Cargando…
Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC
Neoadjuvant immunotherapy may improve outcomes in patients with resectable NSCLC and is being evaluated in phase 2 and 3 studies. Nevertheless, preoperative treatment postpones resection; the potential for increased surgical complexity and greater intra- and postoperative morbidity and mortality is...
Autores principales: | Lee, Jay M., Kim, Anthony W., Marjanski, Tomasz, Falcoz, Pierre-Emmanuel, Tsuboi, Masahiro, Wu, Yi-Long, Sun, Shawn W., Gitlitz, Barbara J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552106/ https://www.ncbi.nlm.nih.gov/pubmed/34746882 http://dx.doi.org/10.1016/j.jtocrr.2021.100221 |
Ejemplares similares
-
Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
por: Yi, Chengxiang, et al.
Publicado: (2019) -
Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC
por: Roller, John F., et al.
Publicado: (2022) -
Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy
por: Shi, Yanhong, et al.
Publicado: (2023) -
Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
por: Chiu, Li-Chung, et al.
Publicado: (2021) -
Is response evaluation criteria in solid tumors (RECIST) effective in patient selection for radical resection after neoadjuvant immunotherapy with advanced NSCLC?
por: Xu, Yuan, et al.
Publicado: (2023)